PRP/Excipient Formulation

About ECI Therapeutics

ECI Therapeutics is a private, preclinical-stage biotech leveraging a unique platform that fuses human platelet-rich plasma-derived growth factors with proprietary biomaterials (hyaluronic acid/chitosan) to create sustained-release therapeutics for tissue repair. Its initial focus is on significant ophthalmic markets, targeting neurotrophic keratitis (a rare disease) and the large, underserved dry eye disease population, with a broader pipeline extending into wound and burn care. Founded in 2018 and based in Cambridge, MA, the company is positioned to address conditions with high unmet need through a potentially safer, more efficacious, and patient-friendly biologic approach.

About ECI Therapeutics

ECI Therapeutics is a private, preclinical-stage biotech leveraging a unique platform that fuses human platelet-rich plasma-derived growth factors with proprietary biomaterials (hyaluronic acid/chitosan) to create sustained-release therapeutics for tissue repair. Its initial focus is on significant ophthalmic markets, targeting neurotrophic keratitis (a rare disease) and the large, underserved dry eye disease population, with a broader pipeline extending into wound and burn care. Founded in 2018 and based in Cambridge, MA, the company is positioned to address conditions with high unmet need through a potentially safer, more efficacious, and patient-friendly biologic approach.

Therapeutic Areas